Gilead Sciences Announces Third Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% as AI buildout costs, Fed rate outlook weigh
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
UPDATE: BMO Capital Maintains Gilead Sciences (GILD) at Market Perform (Correction)
November 2, 2016 6:56 AM EDT(Updated - November 2, 2016 7:17 AM EDT)
(Gilead was not upgraded to Outperform, remains Market Perform at BMO.)
BMO Capital maintained its Market Perform rating on Gilead Sciences (NASDAQ: GILD) with a price target of $84 (prior $98). Comments follow Q3 results.... More
Gilead Sciences (GILD) Misses Q3 EPS by 11c; Reiterates Outlook
November 1, 2016 4:03 PM EDTGilead Sciences (NASDAQ: GILD) reported Q3 EPS of $2.75, $0.11 worse than the analyst estimate of $2.86. Revenue for the quarter came in at $7.4 billion versus the consensus estimate of $7.45 billion.Gilead Sciences reaffirmed FY2016... More
